Full Text Journal Articles by
Author Shanthi Sivendran

Advertisement

Find full text journal articles








Anticancer Therapy at the End of Life: Lessons From a Community Cancer Institute.

Shanthi Sivendran, Selah Lynch, Caitlyn McNaughton, Riley Wong, Sarah Svetec, Jason H Moore, Rachel Holliday, Randall A Oyer, Kristina Newport,

INTRODUCTION:Studies have shown aggressive cancer care at the end of life is associated with decreased quality of life, decreased median survival, and increased cost of care. This study describes the patients most likely to receive systemic anticancer therapy at the end of life in a community cancer institute. MATERIALS AND ... Read more >>

J Palliat Care (Journal of palliative care)
[2019, :825859719851484]

Cited: 0 times

View full text PDF listing >>



Patterns of Support Service, Emergency Department, and Hospital Utilization in Patients with Advanced Cancer: A Descriptive Study.

Caitlyn H McNaughton, Michael Horst, Emily Gehron, Shanthi Sivendran, Julie Nguyen, Rachel Holliday, Kristina Newport,

CONTEXT:Palliative care in oncology provides multiple benefits, however access to specialty palliative clinicians is limited in community cancer centers. Individual support services are more often available, but little is known on the utilization and impact of these services. OBJECTIVES:To describe the utilization of outpatient support services in the advanced cancer ... Read more >>

J Palliat Care (Journal of palliative care)
[2019, :825859719851492]

Cited: 0 times

View full text PDF listing >>



Advertisement

Models of Outpatient Palliative Care Clinics for Patients With Cancer.

Esme Finlay, Kristina Newport, Shanthi Sivendran, Laurel Kilpatrick, Michelle Owens, Mary K Buss,

PURPOSE:Early integration of outpatient palliative care (OPC) benefits patients with advanced cancer and also the health care systems in which these patients are seen. Successful development and implementation of models of OPC require attention to the needs and values of both the patients being served and the institution providing service. ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2019, 15(4):187-193]

Cited: 0 times

View full text PDF listing >>



Illness Understanding of Oncology Patients in a Community-Based Cancer Institute.

Shanthi Sivendran, Sarah Jenkins, Sarah Svetec, Michael Horst, Kristina Newport, Kathleen J Yost, Manshu Yang,

PURPOSE:Several studies have demonstrated that patients have a poor understanding of prognosis, survival, and effectiveness of chemotherapy, particularly in the setting of advanced cancer. This study examines oncology patients' understanding of their illness based on accurate reporting of stage at diagnosis and knowledge of cancer status (ie, free of cancer ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2017, 13(9):e800-e808]

Cited: 1 time

View full text PDF listing >>



Adverse event reporting in oncology clinical trials - lost in translation?

Shanthi Sivendran, Matthew D Galsky,

Expert Opin Drug Saf (Expert opinion on drug safety)
[2016, 15(7):893-896]

Cited: 6 times

View full text PDF listing >>



Previously defined 53 immune gene panel predicts melanoma survival using The Cancer Genome Atlas (TCGA).

Robyn Gartrell, Qian Yingzhi, Lopez Gonzalo, Fu Yichun, White-Stern Ashley, Bansal Mukesh, Sivendran Shanthi, Califano Andrea, Chang Rui, Saenger Yvonne,

J Immunother Cancer (Journal for immunotherapy of cancer)
[2015, 3(Suppl 2):P283-P283]

Cited: 0 times

View full text PDF listing >>



An analysis of the clinical trial landscape for cutaneous melanoma.

Sara Harcharik Perkins, Kristian D Stensland, Matthew D Galsky, Shanthi Sivendran,

Recognizing current trends and obstacles in melanoma clinical trial development is critical to future progress in this field. This article examines the melanoma research enterprise to identify changing trends and potential barriers to success. All trials registered at ClinicalTrials.gov after September 2005 were evaluated for possible inclusion. A total of ... Read more >>

Cutis (Cutis)
[2015, 96(3):186-190]

Cited: 0 times

View full text PDF listing >>



Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies.

Shanthi Sivendran, Kristina Newport, Michael Horst, Adam Albert, Matthew D Galsky,

Manuscript abstracts represent a critical source of information for oncology practitioners. Practitioners may utilize the information contained in abstracts as a basis for treatment decisions particularly when full-text articles are not accessible. In 2007, the Consolidated Standards of Reporting Trials (CONSORT) extension statement for abstracts provided a minimum list of ... Read more >>

Trials (Trials)
[2015, 16:341]

Cited: 5 times

View full text PDF listing >>



Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease.

Shanthi Sivendran, Rui Chang, Lisa Pham, Robert G Phelps, Sara T Harcharik, Lawrence D Hall, Sebastian G Bernardo, Marina M Moskalenko, Meera Sivendran, Yichun Fu, Ellen H de Moll, Michael Pan, Jee Young Moon, Sonali Arora, Ariella Cohain, Analisa DiFeo, Tammie C Ferringer, Mikhail Tismenetsky, Cindy L Tsui, Philip A Friedlander, Michael K Parides, Jacques Banchereau, Damien Chaussabel, Mark G Lebwohl, Jedd D Wolchok, Nina Bhardwaj, Steven J Burakoff, William K Oh, Karolina Palucka, Miriam Merad, Eric E Schadt, Yvonne M Saenger,

Patients with resected stage II-III cutaneous melanomas remain at high risk for metastasis and death. Biomarker development has been limited by the challenge of isolating high-quality RNA for transcriptome-wide profiling from formalin-fixed and paraffin-embedded (FFPE) primary tumor specimens. Using NanoString technology, RNA from 40 stage II-III FFPE primary melanomas was ... Read more >>

J. Invest. Dermatol. (The Journal of investigative dermatology)
[2014, 134(8):2202-2211]

Cited: 15 times

View full text PDF listing >>



Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.

Sara Harcharik, Sebastian Bernardo, Marina Moskalenko, Michael Pan, Meera Sivendran, Heather Bell, Lawrence D Hall, Mireia Castillo-Martín, Kelly Fox, Carlos Cordon-Cardo, Rui Chang, Shanthi Sivendran, Robert G Phelps, Yvonne Saenger,

Accurate assessment of prognosis remains clinically challenging in stage II to III cutaneous melanoma. Studies have implicated CD2 in immune surveillance, T-cell activation, and antitumor immunity, but its role in melanoma progression warrants further investigation.We sought to investigate the prognostic role of CD2 in primary cutaneous melanoma.Patients with American Joint ... Read more >>

J. Am. Acad. Dermatol. (Journal of the American Academy of Dermatology)
[2014, 70(6):1036-1044]

Cited: 6 times

View full text PDF listing >>



Adverse event reporting in cancer clinical trial publications.

Shanthi Sivendran, Asma Latif, Russell B McBride, Kristian D Stensland, Juan Wisnivesky, Lindsay Haines, William K Oh, Matthew D Galsky,

PURPOSE: Reporting adverse events is a critical element of a clinical trial publication. In 2003, the Consolidated Standards of Reporting Trials (CONSORT) group generated recommendations regarding the appropriate reporting of adverse events. The degree to which these recommendations are followed in oncology publications has not been comprehensively evaluated. METHODS: A ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2014, 32(2):83-89]

Cited: 55 times

View full text PDF listing >>



Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis.

Benjamin A Gartrell, Jian Ying, Shanthi Sivendran, Kenneth M Boucher, Toni K Choueiri, Guru Sonpavde, William K Oh, Neeraj Agarwal, Matthew D Galsky,

Mammalian target of rapamycin (mTOR) inhibitors have gained regulatory approval for use in several cancer types. Pulmonary adverse events associated with mTOR inhibitors are well recognized but their frequency has varied considerably among trials. PubMed and ASCO abstracts were searched to identify clinical trials of mTOR inhibitors in solid tumors. ... Read more >>

Target Oncol (Targeted oncology)
[2014, 9(3):195-204]

Cited: 8 times

View full text PDF listing >>



Metabolic complications with the use of mTOR inhibitors for cancer therapy.

Shanthi Sivendran, Neeraj Agarwal, Benjamin Gartrell, Jian Ying, Kenneth M Boucher, Toni K Choueiri, Guru Sonpavde, William K Oh, Matthew D Galsky,

mTOR inhibitors are now approved by regulatory agencies for the treatment of a variety of malignancies. The risk of metabolic complications with these agents is not well characterized.PubMed was searched for articles published from 2001 until 2011. Eligible studies included prospective randomized trials evaluating temsirolimus, everolimus, and ridaforolimus in patients ... Read more >>

Cancer Treat. Rev. (Cancer treatment reviews)
[2014, 40(1):190-196]

Cited: 29 times

View full text PDF listing >>



Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis.

Shanthi Sivendran, Ziyue Liu, Louis J Portas, Menggang Yu, Noah Hahn, Guru Sonpavde, William K Oh, Matthew D Galsky,

BACKGROUND: Several vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKI) are now approved by regulatory agencies and are important in the treatment of solid tumor malignancies. The risk of fatal adverse events (FAEs) with these agents is not well characterized. METHODS: PubMed was searched for articles published from ... Read more >>

Cancer Treat. Rev. (Cancer treatment reviews)
[2012, 38(7):919-925]

Cited: 31 times

View full text PDF listing >>



Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case series.

Shanthi Sivendran, Harold Harvey, Allan Lipton, Joseph Drabick,

Langerhans cell histiocytosis (LCH) is a rare disease caused by a clonal proliferation of specialized dendritic (Langerhans) cells. Although uncommon, it is potentially fatal and carries significant morbidity. Bone involvement is particularly destructive and to date, no standard of care exists for management of both the disease and the significant ... Read more >>

Int. J. Hematol. (International journal of hematology)
[2011, 93(6):782-786]

Cited: 8 times

View full text PDF listing >>



Primary intracranial leiomyosarcoma in an HIV-infected patient.

Shanthi Sivendran, Claudia Irene Vidal, Myra F Barginear,

Primary intracranial leiomyosarcomas are rare tumors arising from the mesenchymal cells of the dura matter or the cerebral blood vessels. Only 14 cases of primary intracranial leiomyosarcoma are reported in the literature. We report a case of primary intracranial leiomyosarcoma in an human immunodeficiency virus-positive patient with a CD4 count ... Read more >>

Int. J. Clin. Oncol. (International journal of clinical oncology)
[2011, 16(1):63-66]

Cited: 10 times

View full text PDF listing >>



Herpes simplex virus oncolytic vaccine therapy in melanoma.

Shanthi Sivendran, Michael Pan, Howard L Kaufman, Yvonne Saenger,

Advanced melanoma is a devastating disease with a five year survival for Stage IV disease of 10 - 20% and a median survival of 6 - 18 months depending on sub-stage. Current FDA approved therapies demonstrate limited response rates, few complete remissions and no proven survival benefit. New therapies are ... Read more >>

Expert Opin Biol Ther (Expert opinion on biological therapy)
[2010, 10(7):1145-1153]

Cited: 20 times

View full text PDF listing >>



Melanoma immunotherapy.

Shanthi Sivendran, Bradley Glodny, Michael Pan, Miriam Merad, Yvonne Saenger,

Melanoma immunotherapy has been an area of intense research for decades, and this work is now yielding more tangible results for patients. Work has focused on 4 main areas: cytokine therapy, administration of immune-modulating antibodies, adoptive T-cell therapy, and vaccines. Cytokine therapy is an established treatment for advanced melanoma, and ... Read more >>

Mt. Sinai J. Med. (The Mount Sinai journal of medicine, New York)
[2010, 77(6):620-642]

Cited: 8 times

View full text PDF listing >>



Ring chromosome 18 abnormality in acute myelogenous leukemia: the clinical dilemma.

Shanthi Sivendran, Stephen Gruenstein, Adriana K Malone, Vesna Najfeld,

The ring chromosome is a circular, structural abnormality composed of either multiple chromosomes or a single chromosome with loss of genetic material at one or both ends. This chromosomal rearrangement is often unstable with frequent recombinations and may be accompanied by either loss or amplification of genetic material[1]. Considering that ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2010, 3:25]

Cited: 5 times

View full text PDF listing >>





Advertisement

Disclaimer
6.049 s